EGFR inhibitor - CS Bay Therapeutics
Latest Information Update: 14 Jul 2022
At a glance
- Originator CS-Bay Therapeutics
- Class Antineoplastics
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 28 Jun 2022 Phase-I clinical trials in Cancer in USA (unspecified route)